Related Experiment Video

Updated: Aug 30, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.6K

Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

Hongzhen Cai1,2, Man Li1,2, Ruiyi Deng1,2

  • 1Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, People's Republic of China.

Biomarker Research
|August 30, 2022
PubMed

Insights

Immunotherapy, particularly targeting PD-1, is a new option for advanced gastric cancer. This review covers biomarkers and clinical trials for enhancing gastric cancer immunotherapy effectiveness.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Gastric cancer presents significant global health challenges with high mortality rates.
  • Current treatments for advanced gastric cancer are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To review molecular biomarkers for gastric cancer immunotherapy.
  • To summarize ongoing clinical trials evaluating these biomarkers and immunotherapies.

Main Methods:

  • Literature review of recent studies on gastric cancer immunotherapy.
  • Analysis of NCCN Guidelines (2022) regarding immunotherapy in gastric cancer.
  • Compilation of data on targeted molecules and clinical trial outcomes.

Main Results:

  • Immunotherapy, primarily targeting Programmed Death 1 (PD-1), is now a first-line option for specific gastric cancer cases.
  • Various other immune checkpoint molecules (CTLA4, LAG3, Tim3, TIGIT) and co-stimulatory molecules (OX40) are under investigation.
  • Clinical trials are exploring the efficacy of these diverse immunotherapeutic strategies.

Conclusions:

  • Immunotherapy represents a promising advancement in treating advanced gastric cancer.
  • Identifying appropriate molecular biomarkers is crucial for optimizing immunotherapy selection and improving patient outcomes.
Keywords:
Anti-PD-1BiomarkerCheckpoint inhibitorGastric cancerImmunotherapy

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.2K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

832

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
496
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
644